1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013

Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 482 pages

Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Central Nervous System (CNS) Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Central Nervous System (CNS) Tumor. Central Nervous System (CNS) Tumor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Central Nervous System (CNS) Tumor.
- A review of the Central Nervous System (CNS) Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Central Nervous System (CNS) Tumor pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Central Nervous System (CNS) Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Central Nervous System (CNS) Tumor pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013
Table of Contents 2
Introduction 6
Central Nervous System (CNS) Tumor Overview 7
Therapeutics Development 8
Central Nervous System (CNS) Tumor Therapeutics under Development by Companies 10
Central Nervous System (CNS) Tumor Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 21
Mid Clinical Stage Products 22
Early Clinical Stage Products 23
Discovery and Pre-Clinical Stage Products 24
Central Nervous System (CNS) Tumor Therapeutics - Products under Development by Companies 25
Central Nervous System (CNS) Tumor Therapeutics - Products under Investigation by Universities/Institutes 34
Companies Involved in Central Nervous System (CNS) Tumor Therapeutics Development 36
Central Nervous System (CNS) Tumor - Therapeutics Assessment 115
Drug Profiles 117
Central Nervous System (CNS) Tumor Therapeutics - Drug Profile Updates 364
Central Nervous System (CNS) Tumor Therapeutics - Discontinued Products 447
Central Nervous System (CNS) Tumor Therapeutics - Dormant Products 448
Central Nervous System (CNS) Tumor - Product Development Milestones 454
Appendix 464

List of Tables


Number of Products Under Development for Central Nervous System (CNS) Tumor, H1 2013 25
Products under Development for Central Nervous System (CNS) Tumor - Comparative Analysis, H1 2013 26
Number of Products under Development by Companies, H1 2013 28
Number of Products under Development by Companies, H1 2013 (Contd..1) 29
Number of Products under Development by Companies, H1 2013 (Contd..2) 30
Number of Products under Development by Companies, H1 2013 (Contd..3) 31
Number of Products under Development by Companies, H1 2013 (Contd..4) 32
Number of Products under Development by Companies, H1 2013 (Contd..5) 33
Number of Products under Development by Companies, H1 2013 (Contd..6) 34
Number of Products under Investigation by Universities/Institutes, H1 2013 36
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 37
Comparative Analysis by Late Stage Development, H1 2013 38
Comparative Analysis by Mid Clinical Stage Development, H1 2013 39
Comparative Analysis by Early Clinical Stage Development, H1 2013 40
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 41
Products under Development by Companies, H1 2013 42
Products under Development by Companies, H1 2013 (Contd..1) 43
Products under Development by Companies, H1 2013 (Contd..2) 44
Products under Development by Companies, H1 2013 (Contd..3) 45
Products under Development by Companies, H1 2013 (Contd..4) 46
Products under Development by Companies, H1 2013 (Contd..5) 47
Products under Development by Companies, H1 2013 (Contd..6) 48
Products under Development by Companies, H1 2013 (Contd..7) 49
Products under Development by Companies, H1 2013 (Contd..8) 50
Products under Investigation by Universities/Institutes, H1 2013 51
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 52
Johnson and Johnson, H1 2013 53
F. Hoffmann-La Roche Ltd., H1 2013 54
Amgen Inc., H1 2013 55
Sanofi-Aventis, H1 2013 56
AstraZeneca PLC, H1 2013 57
Eli Lilly and Company, H1 2013 58
Genentech, Inc., H1 2013 59
Antigenics, Inc., H1 2013 60
MedImmune LLC, H1 2013 61
Lentigen Corporation, H1 2013 62
Sangamo BioSciences, Inc., H1 2013 63
Plexxikon Inc., H1 2013 64
Celltrion, Inc., H1 2013 65
Novartis AG, H1 2013 66
Actelion Ltd, H1 2013 67
Nippon Shinyaku Co., Ltd., H1 2013 69
Pfizer Inc., H1 2013 70
Cell Therapeutics, Inc., H1 2013 71
Exelixis, Inc., H1 2013 72
Aduro BioTech, H1 2013 73
EpiCept Corporation, H1 2013 74
Celldex Therapeutics, Inc., H1 2013 75
ImmunoCellular Therapeutics, Ltd., H1 2013 76
Lixte Biotechnology Holdings, Inc., H1 2013 77
Basilea Pharmaceutica Ltd., H1 2013 78
Northwest Biotherapeutics, Inc., H1 2013 79
Cleveland BioLabs, Inc., H1 2013 80
Oncothyreon Inc, H1 2013 81
Peregrine Pharmaceuticals, Inc., H1 2013 82
Transgene SA, H1 2013 83
Prana Biotechnology Limited, H1 2013 84
Innocell Corporation, H1 2013 85
ThromboGenics NV, H1 2013 86
Rexahn Pharmaceuticals, Inc., H1 2013 87
Nanobiotix, H1 2013 88
Spectrum Pharmaceuticals, Inc., H1 2013 89
Upsher-Smith Laboratories, Inc., H1 2013 90
Nerviano Medical Sciences S.r.l., H1 2013 91
immatics biotechnologies GmbH, H1 2013 92
Apogenix GmbH, H1 2013 93
EnGeneIC Ltd, H1 2013 94
AGY Therapeutics, Inc., H1 2013 95
Ascenta Therapeutics, Inc., H1 2013 96
Diffusion Pharmaceuticals LLC, H1 2013 97
MacroGenics, Inc., H1 2013 98
Fina Biotech, H1 2013 99
Deciphera Pharmaceuticals, LLC, H1 2013 100
Vascular Biogenics Ltd., H1 2013 101
Stemline Therapeutics, Inc., H1 2013 102
BioCancell Therapeutics, Inc., H1 2013 103
Axelar AB, H1 2013 104
Advenchen Laboratories, LLC, H1 2013 105
Viral Genetics, Inc., H1 2013 106
NOXXON Pharma AG, H1 2013 107
ImmunoVaccine Technologies Inc., H1 2013 108
Globeimmune, Inc., H1 2013 109
ChemoCentryx, Inc., H1 2013 110
TVAX Biomedical, LLC, H1 2013 111
Biovista Inc., H1 2013 112
Sirnaomics, Inc., H1 2013 113
Oncovir, Inc., H1 2013 114
TRACON Pharmaceuticals, Inc., H1 2013 115
Nexgenix Pharmaceuticals, LLC, H1 2013 116
Georgia Tech Research Corporation, H1 2013 118
Regulus Therapeutics Inc., H1 2013 119
CLL Pharma, H1 2013 120
DiscoveryBiomed, Inc., H1 2013 121
RECEPTA Biopharma S.A., H1 2013 122
Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2013 123
GreenPeptide Co., Ltd., H1 2013 124
TAU Therapeutics, LLC, H1 2013 126
EirGen Pharma Ltd., H1 2013 127
CytoVac A/S, H1 2013 128
Ampio Pharmaceuticals, Inc., H1 2013 130
CytomX, LLC., H1 2013 131
Assessment by Monotherapy Products, H1 2013 132
Assessment by Combination Products, H1 2013 133
Central Nervous System (CNS) Tumor Therapeutics - Drug Profile Updates 381
Central Nervous System (CNS) Tumor Therapeutics - Discontinued Products 464
Central Nervous System (CNS) Tumor Therapeutics - Dormant Products 465
Central Nervous System (CNS) Tumor Therapeutics - Dormant Products (Contd..1) 466
Central Nervous System (CNS) Tumor Therapeutics - Dormant Products (Contd..2) 467
Central Nervous System (CNS) Tumor Therapeutics - Dormant Products (Contd..3) 468
Central Nervous System (CNS) Tumor Therapeutics - Dormant Products (Contd..4) 469
Central Nervous System (CNS) Tumor Therapeutics - Dormant Products (Contd..5) 470

List of Figures


Number of Products under Development for Central Nervous System (CNS) Tumor, H1 2013 25
Products under Development for Central Nervous System (CNS) Tumor - Comparative Analysis, H1 2013 26
Products under Development by Companies, H1 2013 27
Products under Investigation by Universities/Institutes, H1 2013 35
Late Stage Products, H1 2013 38
Mid Clinical Stage Products, H1 2013 39
Early Clinical Stage Products, H1 2013 40
Discovery and Pre-Clinical Stage Products, H1 2013 41
Assessment by Monotherapy Products, H1 2013 132
Assessment by Combination Products, H1 2013 133

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - ...

Trigeminal Neuralgia - Pipeline Review, H2 2016

Trigeminal Neuralgia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Trigeminal Neuralgia - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Trigeminal Neuralgia - Pipeline Review, H2 2016’, provides an overview of the Trigeminal Neuralgia pipeline landscape. ...

Optic Neuropathy - Pipeline Review, H2 2016

Optic Neuropathy - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Optic Neuropathy - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Optic Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Optic Neuropathy pipeline landscape. The report ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.